A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

201630 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: Breast Cancer Research and Treatment

Volume 156, Issue 2, pp. 319-330

Field-Weighted Citation Impact: 5.14